Browsing Tag
narcolepsy
5 posts
Alkermes raises Avadel bid to $2.37bn with enhanced CVR terms tied to LUMRYZ FDA milestone
Alkermes raises Avadel bid to $2.37B with improved CVR linked to FDA approval for LUMRYZ in idiopathic hypersomnia. Read the full transaction breakdown.
Centessa Pharmaceuticals pulls off massive $225m deal—Stock price jumps
Centessa Pharmaceuticals has experienced a substantial rise in its share price after completing an upsized public offering of…
Suven Life Sciences announces positive results from Samelisant Phase-2 study
Suven Life Sciences, a pioneering biopharmaceutical company specializing in Central Nervous System (CNS) disorders, recently announced the successful…
Takeda halts TAK-994 narcolepsy treatment development due to hepatotoxicity concerns
Takeda’s pioneering Phase 2 trial of TAK-994, a potential treatment for narcolepsy type 1 (NT1), came to an…
Suven Life Sciences set to begin samelisant phase 2 trial in narcolepsy
Suven Life Sciences has announced the successful completion of enrollment for its phase-2 proof-of-concept (PoC) clinical study to…